Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord mesenchymal stem cells for infection-related ARDS
ChiCTR2400081032Phase 2Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Feb 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in acute respiratory distress syndrome (ARDS), sponsored by China-Japan Friendship Hospital. Primary endpoints: Adverse events and Dose-limiting toxicity. Started Feb 2024; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2400081032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081032.